Ozempic® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction or nonfatal stroke) in adults with type 2 diabetes mellitus and established CVD. View Limitations of Use.
See the efficacy data from the Ozempic® clinical trial program
aResults apply to Ozempic® plus standard of care vs standard of care alone in SUSTAIN 6 trial.
MACE=CV death, nonfatal myocardial infarction, or nonfatal stroke.